Literature DB >> 31343474

Supply Chain Delays in Antimicrobial Administration After the Initial Clinician Order and Mortality in Patients With Sepsis.

Markos G Kashiouris1,2, Zachary Zemore3, Zachary Kimball2, Christos Stefanou4, Alpha A Fowler1, Bernard Fisher1, Marjolein de Wit1, Sammy Pedram1,2, Curtis N Sessler1,2.   

Abstract

OBJECTIVES: There is mounting evidence that delays in appropriate antimicrobial administration are responsible for preventable deaths in patients with sepsis. Herein, we examine the association between potentially modifiable antimicrobial administration delays, measured by the time from the first order to the first administration (antimicrobial lead time), and death among people who present with new onset of sepsis.
DESIGN: Observational cohort and case-control study.
SETTING: The emergency department of an academic, tertiary referral center during a 3.5-year period. PATIENTS: Adult patients with new onset of sepsis or septic shock.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We enrolled 4,429 consecutive patients who presented to the emergency department with a new diagnosis of sepsis. We defined 0-1 hour as the gold standard antimicrobial lead time for comparison. Fifty percent of patients had an antimicrobial lead time of more than 1.3 hours. For an antimicrobial lead time of 1-2 hours, the adjusted odds ratio of death at 28 days was 1.28 (95% CI, 1.07-1.54; p = 0.007); for an antimicrobial lead time of 2-3 hours was 1.07 (95% CI, 0.85-1.36; p = 0.6); for an antimicrobial lead time of 3-6 hours was 1.57 (95% CI, 1.26-1.95; p < 0.001); for an antimicrobial lead time of 6-12 hours was 1.36 (95% CI, 0.99-1.86; p = 0.06); and for an antimicrobial lead time of more than 12 hours was 1.85 (95% CI, 1.29-2.65; p = 0.001).
CONCLUSIONS: Delays in the first antimicrobial execution, after the initial clinician assessment and first antimicrobial order, are frequent and detrimental. Biases inherent to the retrospective nature of the study apply. Known biologic mechanisms support these findings, which also demonstrate a dose-response effect. In contrast to the elusive nature of sepsis onset and sepsis onset recognition, antimicrobial lead time is an objective, measurable, and modifiable process.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31343474     DOI: 10.1097/CCM.0000000000003921

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  SEP-1 Has Brought Much Needed Attention to Improving Sepsis Care…But Now Is the Time to Improve SEP-1.

Authors:  Chanu Rhee; Jeffrey R Strich; Michael Klompas; Donald M Yealy; Henry Masur
Journal:  Crit Care Med       Date:  2020-06       Impact factor: 7.598

2.  Delays in Time-To-Antibiotics for Young Febrile Infants With Serious Bacterial Infections: A Prospective Single-Center Study.

Authors:  Jinghui Yang; Wei Jie Ong; Rupini Piragasam; John Carson Allen; Jan Hau Lee; Shu-Ling Chong
Journal:  Front Pediatr       Date:  2022-04-29       Impact factor: 3.569

3.  Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance.

Authors:  Jeffrey R Strich; Emily L Heil; Henry Masur
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

4.  Identifying High-Risk Subphenotypes and Associated Harms From Delayed Antibiotic Orders and Delivery.

Authors:  Xuan Han; Alexandra Spicer; Kyle A Carey; Emily R Gilbert; Neda Laiteerapong; Nirav S Shah; Christopher Winslow; Majid Afshar; Markos G Kashiouris; Matthew M Churpek
Journal:  Crit Care Med       Date:  2021-10-01       Impact factor: 9.296

Review 5.  Management of sepsis and septic shock in the emergency department.

Authors:  Francesco Gavelli; Luigi Mario Castello; Gian Carlo Avanzi
Journal:  Intern Emerg Med       Date:  2021-04-22       Impact factor: 3.397

6.  DeepAISE - An interpretable and recurrent neural survival model for early prediction of sepsis.

Authors:  Supreeth P Shashikumar; Christopher S Josef; Ashish Sharma; Shamim Nemati
Journal:  Artif Intell Med       Date:  2021-02-13       Impact factor: 5.326

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.